Viral Hemorrhagic Fever Overview

Save information for later
Sign Up

Learn About Viral Hemorrhagic Fever

What is the definition of Viral Hemorrhagic Fever?
Viral hemorrhagic fevers is a term used to describe a group of illnesses caused by four different families of viruses that severely affect multiple body systems. Some of the more commonly known types of viral hemorrhagic fevers include Ebola virus, Lassa fever, Hantavirus, Tick-borne encephalitis, and Rift Valley fever. Viral hemorrhagic fevers are carried by insects, rats, and mice and are limited to specific geographical areas in which the insects and animals live, such as West Africa (Lassa fever). While humans can be infected by contact with an infected insect or animal, these viruses can also be transmitted from one human to another and are highly contagious.
What are the symptoms of Viral Hemorrhagic Fever?
While certain types of viral hemorrhagic fevers may cause only mild illness, many of these can cause severe, life-threatening symptoms, and even death. Symptoms may also include muscle aches, extreme fatigue, and high fever. An infected person’s vascular system is often damaged, while the body loses ability to regulate. Vascular damage causes hemorrhage (bleeding).
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Viral Hemorrhagic Fever?
Most viral hemorrhagic diseases have no treatment. However, the antiviral drug, ribavirin, may help to shorten the course of illness, and, in some cases, may even prevent infection. Patients are mainly treated with supportive care, which includes prevention of dehydration. Some patients may need kidney dialysis in the event of kidney failure.
Who are the top Viral Hemorrhagic Fever Local Doctors?
David C. Lye
Elite in Viral Hemorrhagic Fever
David C. Lye
Elite in Viral Hemorrhagic Fever
David C. Lye
12 Science Drive 2, 
Singapore, SG 

David Lye practices in Singapore, Singapore. Mr. Lye is rated as an Elite expert by MediFind in the treatment of Viral Hemorrhagic Fever. His top areas of expertise are Dengue Fever, Viral Hemorrhagic Fever, Methicillin-Resistant Staphylococcus Aureus (MRSA), COVID-19, and Hepato-Pancreato-Biliary Surgery.

Stephan D. Gunther
Elite in Viral Hemorrhagic Fever
Stephan D. Gunther
Elite in Viral Hemorrhagic Fever
Stephan D. Gunther
Bernhard Nocht Str. 74, 
Hamburg, HH, DE 

Stephan Gunther practices in Hamburg, Germany. Mr. Gunther is rated as an Elite expert by MediFind in the treatment of Viral Hemorrhagic Fever. His top areas of expertise are Lassa Fever, Viral Hemorrhagic Fever, Ebola Virus Disease, and Marburg Hemorrhagic Fever.

 
 
 
 
Learn about our expert tiers
Learn More
Johan Neyts
Elite in Viral Hemorrhagic Fever
Johan Neyts
Elite in Viral Hemorrhagic Fever
Johan Neyts

Immunology And Transplantation, VirusBank Platform, KU Leuven

Leuven, VLG, BE 

Johan Neyts practices in Leuven, Belgium. Mr. Neyts is rated as an Elite expert by MediFind in the treatment of Viral Hemorrhagic Fever. His top areas of expertise are Yellow Fever, Hepatitis E, Viral Hemorrhagic Fever, Parainfluenza Virus Type 3, and Lung Transplant.

View All Doctors
What are the latest Viral Hemorrhagic Fever Clinical Trials?
Long-Term Neurologic and Neurocognitive Sequelae Following Pediatric Ebola Virus in Liberia
Long-Term Neurologic and Neurocognitive Sequelae Following Pediatric Ebola Virus in Liberia
Enrollment Status: Recruiting
Publish Date: October 15, 2025

Background: Ebola virus disease (EVD) causes fever, vomiting, and diarrhea, and may cause internal bleeding. It is often fatal. EVD may also damage the brain and nervous system. It can cause headaches, tremors, weakness, and other problems. These issues can continue for years after people recover from EVD infection. Researchers want to understand more about how EVD may have affected the brains of people who c...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Immunogenicity, and Efficacy of V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Immunogenicity, and Efficacy of V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Biological
Study Phase: Phase 3

Summary: The purpose of this study is to demonstrate that V181 is safe and well tolerated, elicits an immune response, and reduces the frequency of virologically confirmed dengue (VCD) of any severity, due to any of the 4 dengue serotypes, regardless of dengue serostatus at baseline in children 2 to 17 years of age.

View All Clinical Trials